Chordia Therapeutics Inc. (TYO:190A)

Japan flag Japan · Delayed Price · Currency is JPY
155.00
+4.00 (2.65%)
Apr 28, 2026, 3:30 PM JST
-35.15%
Market Cap 11.43B
Revenue (ttm) n/a
Net Income (ttm) -1.44B
Shares Out 73.73M
EPS (ttm) -20.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 509,500
Average Volume 852,675
Open 149.00
Previous Close 151.00
Day's Range 149.00 - 155.00
52-Week Range 98.00 - 243.00
Beta n/a
RSI 68.64
Earnings Date Apr 14, 2026

About Chordia Therapeutics

Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2017
Employees 23
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 190A
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.